Literature DB >> 6175787

Systemic administration of human leukocyte interferon to melanoma patients. I. Effects on natural killer function and cell population.

S H Golub, F Dorey, D Hara, D L Morton, M W Burk.   

Abstract

Natural killer (NK) cytotoxicity was assessed against K562 targets in 14 melanoma patients who received daily im doses of human leukocyte interferon (IFN) for 42 consecutive days. The most common pattern of NK activity was a decline from pretreatment levels 1 day after initiation of treatment, followed by increasing cytotoxicity with peak activity at day 7 and a subsequent gradual decline to pretreatment levels during the remaining weeks of treatment. This pattern was particularly apparent in patients who received 3 x 10(6) or 9 x 10(6) U IFN/day, while patients who received 1 X 10(6) U IFN/day tended to lack the decline at day 1 and maintained the elevated NK activity past day 7. Changes in NK activity could not be related to changes in absolute lymphocyte counts; to proportions of cells bearing membrane receptors for erythrocyte-antibody-complement, of cells bearing FC gamma receptor; or to clinical response to IFN.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6175787

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  13 in total

1.  Application of a new method for detecting the phenotype of target binding cells.

Authors:  R A Lindemann; J A Jenkins; R A Figlin; S H Golub
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  The inhibitory effect of human interferon alpha on the generation of lymphokine-activated killer activity.

Authors:  Y Tokuda; N Ebina; S H Golub
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Modification of natural killer activity of lymphocytes infiltrating human lung cancers.

Authors:  T M Anderson; Y Ibayashi; E C Holmes; S H Golub
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

4.  Interferon-alpha conjugation to human osteogenic sarcoma monoclonal antibody 791T/36.

Authors:  J M Pelham; J D Gray; G R Flannery; M V Pimm; R W Baldwin
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

5.  The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.

Authors:  Gregory B Lesinski; Mirela Anghelina; Jason Zimmerer; Timothy Bakalakos; Brian Badgwell; Robin Parihar; Yan Hu; Brian Becknell; Gerard Abood; Abhik Ray Chaudhury; Cynthia Magro; Joan Durbin; William E Carson
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

6.  Treatment of patients with transitional cell carcinoma of the urinary bladder with intravesical poly I: poly C effects on natural killer function.

Authors:  C Moroz; B Kupfer; A Lindner; M Many
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Phase-I trial of UltrapureTM human leukocyte interferon in human malignancy.

Authors:  G T Budd; R M Bukowski; L Miketo; B Yen-Lieberman; M R Proffitt
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study.

Authors:  A Balsari; R Marolda; C Gambacorti-Passerini; G Sciorelli; G Tona; E Cosulich; D Taramelli; G Fossati; G Parmiani; N Cascinelli
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 9.  Natural killer cells in human solid tumors.

Authors:  M Introna; A Mantovani
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

10.  In vitro modulation of human natural killer cell activity by interferon: generation of adherent suppressor cells.

Authors:  A Uchida; E Yanagawa; E M Kokoschka; M Micksche; H S Koren
Journal:  Br J Cancer       Date:  1984-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.